Ki-67 [SP6] Antibody – 153Eu

Catalog: 715302
Clone: SP6
Isotype: Rabbit IgG
Reactivity: Human*, Mouse*
Application: MIBI-FFPE
Storage: Supplied in antibody stabilizer with 0.05% sodium azide. Store at 4°C

IHC: Ki-67 staining of FFPE human tonsil


MIBI: Ki-67 staining (cyan) of FFPE human tonsil, costained with dsDNA (magenta)


IHC: Ki-67 staining of FFPE mouse spleen


MIBI: Ki-67 staining (cyan) of FFPE mouse spleen, costained with dsDNA (magenta)

Background: Ki-67 is a nuclear protein expressed by proliferating cells (cells in G1, S, G2, and mitosis, absent in the G0 resting phase). The Ki-67 protein has a half-life of only 1–1.5 hours. The Ki-67 proliferation index, or fraction of Ki-67-positive tumor cells, is associated with the clinical course of certain cancers, including carcinomas of the prostate, brain and breast and gastroenteropancreatic neuroendocrine tumors. Antisense oligonucleotides and antibodies targeting Ki-67 have been reported to inhibit cell cycle progression.

Validation: Each lot of conjugated antibody is quality control tested by staining tissue following the MIBI Staining Protocol optimized for the applicable tissue format with subsequent MIBIscope analysis using the appropriate positive and negative tissue field of views.

Recommended Usage: Mouse FFPE: 1 ug/mL dilution. For optimal results, the antibody should be titrated for each desired application.

MIBI technology: Learn more about MIBI Technology, a multiplex IHC technology with unmatched sensitivity and true subcellular resolution.

Li L.T., Jiang G., Chen Q., Zheng J.N. Ki67 is a promising molecular target in the diagnosis of cancer. Mol Med Rep. 2015;11(3):1566-72.
Rahmanzadeh, R., Rai, P., Celli, J.P., Rizvi, I., Baron-Lühr, B., Gerdes, J., Hasan, T. Ki-67 as a molecular target for therapy in an in vitro three-dimensional model for ovarian cancer. Cancer Res. 2010; 70(22):9234-42.

* Conjugate tested on human tissue and mouse tissue.

Contact Us

<p style="text-align: center; margin-top: 2em;">Let us know how we can help you.</p>

    Immuno-oncology/CancerNeuroscienceInfectious DiseaseImmunologyStem CellOther


    Please contact me. I understand that I can choose to unsubscribe at any time by e-mailing

    Contact Us

    We are using cookies on our website

    Please confirm, if you accept our tracking cookies. You can also decline the tracking and continue to visit our website without any data sent to third-party services.